dr.lucasluquetti — Supported | PeptIQ Claim Auditor

Audited July 19, 2026 · Post from Nov 21, 2025

✅Supported

SS-31 (elamipretide) has credible preclinical support for reducing oxidative stress and enhancing mitochondrial bioenergetic performance in cell culture and animal models. The oxidative stress reduction claim is well-documented across multiple independent studies. However, all available evidence is from in-vitro or animal research; no peer-reviewed human clinical trials confirming these outcomes in humans were found. The claim about 'improved cellular function' lacks specific literature. Creators should note that while the mechanistic direction is scientifically supported, human efficacy remains unproven.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/68d3a0fe…

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

O SS-31 acaba de ser liberado pela FDA. Um peptídeo mitocondrial que reduz estresse oxidativo, melhora a função celular e potencializa a performance metabólica. A ciência segue avançando e nós seguimos juntos.

Video transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.

Claim breakdown

3 claims

“SS-31 reduces oxidative stress.”

✅Supported

Multiple peer-reviewed studies demonstrate SS-31 (elamipretide) reduces oxidative stress through mitochondrial-targeted mechanisms. A 2025 in-vitro study (PMID: 39848110) in cardiomyocytes shows SS-31@Fer-1 significantly reduced oxidative stress markers (increased GPX4, decreased ACSL4/PTGS2, maintained iron homeostasis); a 2019 mouse study (PMID: 31747905) confirmed SS-31 reduces oxidative stress and mitochondrial dysfunction in LPS-induced neuroinflammation. Evidence tier: preclinical (cell culture and animal models), but mechanistically consistent across multiple independent investigations.

Supporting studies

“SS-31 improves cellular function.”

❌No Evidence

No peer-reviewed studies, registered clinical trials, or PubMed abstracts were found specifically addressing whether SS-31 'improves cellular function' as a standalone claim. While the oxidative stress and mitochondrial studies (PMID: 39848110, 31747905) do show improved cell viability and reduced cytotoxicity markers (LDH, CK-MB, apoptosis), no literature was retrieved that directly tests or reports on 'cellular function' as a defined outcome measure for SS-31.

Supporting studies

“SS-31 enhances metabolic performance.”

✅Supported

Literature supports SS-31 enhancing metabolic/bioenergetic performance in preclinical models. The 2019 mouse study (PMID: 31747905) demonstrates improved mitochondrial function and synaptic performance; a 2026 Sports Medicine review (PMID: 41966639) lists SS-31 among unapproved peptides showing 'favorable tissue repair and metabolic outcomes in animal models.' Evidence tier: preclinical (animal and in-vitro), with no human clinical trials yet published—limiting certainty of real-world metabolic enhancement in humans.

Supporting studies

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error